About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, December 4th, 2015

The QualityStocks
Daily Stock List


Inception Mining, Inc. (IMII)

Streetwise Reports, PennyStocks24, Information Solutions Group, and Charms Investments LTD reported previously on Inception Mining, Inc. (IMII), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Inception Mining, Inc. engages in the acquisition, exploration, and development of precious metal properties (mainly gold-related). A minerals resource enterprise, the Company’s principal target properties are those that have been the subject of historical exploration having significant supporting data. Inception Mining is based in Salt Lake City, Utah and the Company’s shares trade on the OTC BB.

Inception Mining holds interest in the U.P. and Burlington Gold Mine. This includes two Federal patented mining claims situated in the County of Lemhi, Northwest of Salmon, Idaho. The U.P. and Burlington Mine is within the Salmon National Forest. The mine is considered to be within the Eureka Mining District.

Inception Mining has compiled a two-phase plan in which it intends to fund underground mining with operating profits from surface mining, if any. The Company announced in August 2014 that it entered into an Ore Processing Agreement with New Jersey Mill Joint Venture (NJ Mill), a floatation mill that can process 360 metric tonnes daily. This mill is in Kellogg, Idaho. NJ Mill will process Inception Mining's bulk samples. NJ Mill is jointly owned by New Jersey Mining Company (NJMC) and Crescent Silver, LLC. NJ Mill is managed by New Jersey Mining Company.

Inception Mining is looking to expand the current NI 43-101 Technical Analysis to a full Reserve Confirmation. Historical reports and many recent assay results indicate ore grades potentially exceeding 0.5 oz/ton Gold (Au) and recoverable amounts of Silver (Ag) are also contained in the exposed veins. Inception (if favorable results are returned from this program) would then direct its efforts to the completion of a small underground mine plan this year.

This past October, Inception Mining announced that the August, September, and partial October production of Clavo Rico Ltd., its wholly-owned subsidiary, has surpassed 1500 ounces of gold and 2500 ounces of silver. The Company has closed the merger with Clavo Rico. It has assumed management control of its main operation, the Cerros Del Sur operation in Honduras, Central America. Clavo Rico has principal operations in Honduras. Clavo Rico operates two subsidiaries with positive revenue. It also holds other mining concessions. Clavo Rico’s workings include several historical underground operations dating back to the early Mayan and Spanish occupation.

Inception Mining, Inc. (IMII), closed Friday's trading session at $0.25, down 7.24%, on 529 volume with 7 trades. The average volume for the last 60 days is 599 and the stock's 52-week low/high is $0.0501/$0.44.

Lightwave Logic, Inc. (LWLG)

SmallCapVoice, PennyStocks24, SmallCap Fortunes, StockGuru, FeedBlitz, OTC Picks, Standout Stocks, and HotOTC reported earlier on Lightwave Logic, Inc. (LWLG), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Lightwave Logic is a technology business concentrating on the development of Next Generation Photonic Devices and Non Linear Optical Polymer Materials Systems for applications in high-speed fiber-optic telecommunications and data communications. It creates prototype electro-optic demonstration devices and is moving toward commercialization of its high-activity, high-stability organic polymers for applications in electro-optical device markets. Lightwave Logic is headquartered in Longmont, Colorado.
The Company has several U.S. and international patent applications. These cover Lightwave Logic’s composition of matter and spacer systems. Patents have been issued covering its basic Heterocyclical Chromophore Architecture and the Tricyclic Spacer systems.

Lightwave Logic is utilizing organic nonlinear electro-optical and all-optical polymers (plastic) as the foundation for a series of proprietary (internal and licensed to external partners) advanced Integrated Optical Devices, which have wide-ranging application in telecommunications, data communications, as well as optical computing for use in military and commercial markets.  
It has integrated its proprietary Perkinamine™ chromophore technology with other chromophores based in part on aspects of proprietary, in-licensed technologies. This has resulted in a strong and durable nonlinear organic electro-optical (EO) material that will be employed in photonic device development. It is based on its multi-chromophore approach, which permits two or more chromophores to work together.

Lightwave Logic previously announced that initial thermal aging testing on its organic polymers indicates decades of operational performance as the Company prepares to process a series of commercially viable bleached waveguide devices. These are the initial products in a planned photonic device program. It is also initiating side-by-side comparative testing of its organic polymers versus duplicate silicon photonic devices. The expectation is that such testing will provide results of its organic polymers' ability to improve a wide array of performance parameters on photonic devices.

Last month, Lightwave Logic announced that it successfully completed the fabrication of organic polymer ridge waveguide structures with its core material and has now commenced passive testing. In addition, it also announced that its organic multi-chromophore polymer material systems have exceeded 2,000 hours of photochemical stability testing.

Lightwave Logic, Inc. (LWLG), closed Friday's trading session at $0.6573, down 0.41%, on 44,415 volume with 27 trades. The average volume for the last 60 days is 63,293 and the stock's 52-week low/high is $0.59/$1.02.

CytoDyn, Inc. (CYDY)

PennyStockRumors and AllPennyStocks reported previously on CytoDyn, Inc. (CYDY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

CytoDyn, Inc. is a biotechnology company concentrating on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection - PRO 140. PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in man. CytoDyn is based in Vancouver, Washington.

PRO 140 is the Company’s novel self-injectable antibody for the treatment of HIV. PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells. PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors. The intention of these are to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results so far indicate that it does not affect the normal function of the cell.

PRO 140 has been the subject of four Phase 1/1b and two Phase 2a clinical trials. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can considerably reduce viral burden in people infected with HIV. CytoDyn’s intention is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.    

PRO 140 has also been designated a "fast track" product candidate by the Food and Drug Administration (FDA). The PRO 140 antibody appears to be a strong antiviral agent leading to potentially fewer side effects and less frequent dosing requirements in comparison to daily drug therapies now in use.

CytoDyn has reached an agreement with the FDA on the Company's previously submitted Phase 3 protocol synopsis for PRO 140. Its Phase 3 protocol provides for a 25-week study with 300 HIV patients. The Company’s recently completed Phase 2b treatment substitution trial demonstrated that 98 percent of all patients treated with PRO 140 successfully passed four weeks of monotherapy without virologic failure.

CytoDyn announced this past June that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer. In August, CytoDyn announced that it started its first clinical site for its Phase 3 trial. Moreover, CytoDyn announced in October that the first patient in its Phase 3 clinical trial was injected with PRO 140.

CytoDyn, Inc. (CYDY), closed Friday's trading session at $0.835, up 1.21%, on 22,858 volume with 16 trades. The average volume for the last 60 days is 96,692 and the stock's 52-week low/high is $0.63/$1.20.

Security Devices International, Inc. (SDEV)

Nebula Stocks reported previously on Security Devices International, Inc. (SDEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Security Devices International (SDI), Inc. is a defense technology company listed on the OTC Market’s OTCQB. The Company specializes in the sale of innovative, next generation non-lethal ammunition. At present, SDI is deploying its family of non-lethal ammunition to foreign militaries, law enforcement, correctional services, and homeland security agencies worldwide. Founded in 2005, SDI has its corporate office in Tampa, Florida.

SDI is in the market-entry phase of deploying its family of non-lethal ammunition to global military law enforcement and correctional agencies. SDI rounds have undergone development to be used at longer ranges to ensure safety of the user and provide an effective means to incapacitate subjects without causing lethal injury.

The Company’s solutions are a safer alternative to conventional crowd control devices now in the marketplace, including bean-bags, batons, and plastic and rubber bullets. Its products include the BIP (Blunt Impact Projectile), its full line of payload ammunition, and the WEP (Wireless Electric Projectile). The BIP and WEP line of ammunitions incorporate an inventive collapsible head for kinetic energy mitigation, which makes it highly effective even at very close range.

The BIP’s collapsible head allows for more surface contact, and therefore greater pain compliance. SDI’s WEP uses mini harpoons to affix the bullet to the target’s clothing and body. WEP releases a charge, electro-neural muscular impulse. It is a customized product for a specialty market.

In late October, SDI provided a corporate update. Recent Correctional Services (penitentiaries) sales include agencies in Regina, Saskatchewan; Grand Cache, Alberta; Saskatoon, Saskatchewan; Kingston, Ontario; and West Virginia, U.S. Purchasing Police Departments who have also been added to the list of government agencies include Portland, Oregon; Lompoc, California; Los Alamos, New Mexico; Toronto, Ontario; Montreal, Quebec, and Hartford, Connecticut. In addition, the Company’s rounds were bought by a Federal agency in Alberta, Canada, a State Police agency in the mid-western U.S., and also numerous Sheriff’s departments in California.

Security Devices International, Inc. (SDEV), closed Friday's trading session at $0.27, even for the day, on 500 volume with 1 trade. The average volume for the last 60 days is 23,656 and the stock's 52-week low/high is $0.20/$0.50.

Arno Therapeutics, Inc. (ARNI)

Streetwise Reports and SmallCapVoice reported on Arno Therapeutics, Inc. (ARNI), and today we also highlight the Company, here at the QualityStocks Daily Newsletter.

Arno Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Flemington, New Jersey. The Company primarily centers on the development of therapeutics for the treatment of cancer and other life threatening diseases. It has exclusive international rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors, and also infectious diseases.

Arno Therapeutics’ product pipeline includes Onapristone, AR-42, and AR-12. Onapristone is a progesterone receptor antagonist. It has demonstrated anti-tumor activity in preclinical and clinical studies of hormone-dependent tumors. AR-42 is a novel, oral agent therapy now in early clinical development. AR-12 is an orally-available small molecule.

Regarding AR-12, preliminary data demonstrate that the mechanism of action may include induction of host cell autophagy and inhibition of fungal acetyl coenzyme A synthetase. Previously, AR-12 completed Phase 1 clinical trials in patients with cancer. Additional pre-clinical research indicates that AR-12 may have potential as an antimicrobial agent in different infectious diseases.

This year, Arno Therapeutics announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), designated AR-12 as an orphan medicinal product for the treatment of two separate infectious diseases, cryptococcosis and tularaemia. The European Commission grants orphan designations for medicines that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU and where no satisfactory treatment is available.

Recently, Arno Therapeutics announced data demonstrating that AR-12 is a promising novel antifungal agent for the treatment of onychomycosis with activity against two primary fungal organisms responsible for causing the condition. Onychomycosis is a common fungal infection of the fingernails and toenails.

Additionally, recent selected highlights for Arno Therapeutics include initiating the second stage of a Phase I/II trial of onapristone in men with advanced, castration-resistant prostate cancer (CRPC). It also continued to actively screen and enroll patients in a Phase II trial of onapristone in women with recurrent or metastatic endometrioid tumors that have been shown to express the activated form of the progesterone receptor (APR), and who have received no greater than one prior chemotherapy and no prior hormone therapy.

Arno Therapeutics, Inc. (ARNI), closed Friday's trading session at $0.34, even for the day, on 5,000 volume with 2 trades. The average volume for the last 60 days is 14,869 and the stock's 52-week low/high is $0.21/$1.15.


The QualityStocks
Company Corner


Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.075, off by 15.73%, on 180,533 volume with 15 trades. The stock’s average daily volume over the past 60 days is 95,194, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation

Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report

Nutra Pharma to Present at Upcoming Investment Conference

OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.93, up 3.91%, on 17,150 volume with 6 trades. The stock’s average daily volume over the past 60 days is 5,719, and its 52-week low/high is $0.45/$1.00.

OurPet's Company today announced that Dean Tsengas has been unanimously voted by the Board of Directors to Chief Operations Officer. His appointment is effective December 7 and he will be overseeing Operations, Global Logistics, Quality Assurance, and Product Development. Since the founding of OurPet's in 1994, as the Vice President of OurPet's Company, Tsengas has played a key role in the launch of the pet-products venture and has held various engineering, marketing and operational responsibilities. Under his managerial guidance OurPet's has developed extensive supply chain management, sourcing, warehouse, and QA capabilities.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

Dean Tsengas Named Chief Operations Officer of OurPet's Company

OurPet's Company (OPCO) Named 'Company of the Month' in November Issue of The Bowser Report

OurPet's Company Reports Q3 2015 Results, Including Record Net Revenue of Nearly $6.0 Million -- Net Income Up 428% to $410,450

Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.179, up 15.48%, on 94,626 volume with 10 trades. The stock’s average daily volume over the past 60 days is 34,520, and its 52-week low/high is $0.0137/$0.55.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Giggles N’ Hugs Signs Agreement with New York-Based Chardan Capital Markets

Giggles N Hugs to present at the 8th annual LD Micro Conference main event

Westfield Seeks To Expand Partnership with Giggles N Hugs

Oakridge Global Energy Solutions, Inc. (OGES)

The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.50, up 4.17%, on 29,191 volume with 21 trades. The stock’s average daily volume over the past 60 days is 20,288, and its 52-week low/high is $0.15/$2.40.

Oakridge Global Energy Solutions, Inc. (OGES) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market. Disclaimer

Oakridge Global Energy Solutions, Inc. Company Blog

Oakridge Global Energy Solutions, Inc. News:

Oakridge Global Energy Solutions Announces Q3 Results

Oakridge Global Energy Solutions to Be Showcased In Upcoming “New To The Street” Series

Oakridge Announces Addition of Three Independent Board Members

Latitude 360, Inc. (LATX)

The QualityStocks Daily Newsletter would like to spotlight Latitude 360, Inc. (LATX). Today, Latitude 360, Inc. closed trading at $0.0039, up 2.63%, on 355,150 volume with 15 trades. The stock’s average daily volume over the past 60 days is 4,034,867, and its 52-week low/high is $0.0022/$1.47.

Latitude 360, Inc. (LATX) is an award-winning pioneer of a dining and entertainment venues that combine premier upscale casual dining with numerous state-of-the-art entertainment choices. The company develops, constructs and operates cutting-edge Latitude 360 venues ranging from 35,000-85,000 sq. ft., packed full of eating and entertainment options that appeal to a broad base of guests, private events and corporate clients.

Through its three current award-winning locations in Jacksonville, Florida, Pittsburgh, Pennsylvania, and Indianapolis, Indiana, Latitude 360 employs roughly 500 talented individuals working to deliver the brand's unique "360 EXPERIENCE" which fuses the magic of exceptional food and beverage with multiple entertainment options in upscale, contemporary-designed venues. Key offerings at each 360 location include Las Vegas-style live performance showroom, a feature bar featuring the area's top musicians and/or DJs, luxury bowling, dine-in movies, high-definition sports theatre, game arcade and luxury cigar lounge and many choices of private meeting space.

In 2014 Latitude 360 launched the first-of-its-kind monthly club membership program which provides guests with a cache of monthly entertainment assets at a value price as well as exclusive access to a 360 Club Concierge service – all for a monthly fee. The program has quickly grown to more than 5,000 monthly paying members.

Latitude 360 recently expanded its entertainment offerings when it acquired Major League Fantasy (MLF), a leader in the daily fantasy sports industry. By implementing "360 Fantasy Live" into is existing locations, Latitude 360 is making a strong entrance into a rapidly growing market expected to reach $6 billion-$10 billion by year-end 2016. The acquisition of MLF allows Latitude 360 to position itself as one of the first live, multimedia venues to offer in-house, high-stakes, competitive daily fantasy events.

Led by an experienced and visionary management team, Latitude 360 is focused on further expanding its brick and mortar locations and anticipates opening additional 360 venues overseas and domestically in major cities like New York, Boston, Atlantic City and Chicago. Disclaimer

Latitude 360, Inc. Company Blog

Latitude 360, Inc. News:

Multi-Dimensional Entertainment Eatery Latitude 360 Enhances Guest Experience and Engagement Through Partnership With MyCheck

NFL Week One Contests Now Available on 360 Fantasy Live.com

Latitude 360 Officially Launches "360 Fantasy Live"


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251